"Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults"
作者全名:"Song, Rui; Li, Zhao; Zhang, Yingzhi; Tan, Jiahe; Chen, Zhiwei"
作者地址:"[Song, Rui; Zhang, Yingzhi; Chen, Zhiwei] Chongqing Med Univ, Inst Viral Hepatitis, Dept Infect Dis, Key Lab Mol Biol Infect Dis,Affiliated Hosp 2,Mini, Chongqing, Peoples R China; [Li, Zhao] Seventh Peoples Hosp Chongqing, Dept Gastroenterol, Chongqing, Peoples R China; [Tan, Jiahe] Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing, Peoples R China; [Chen, Zhiwei] Chongqing Med Univ, Inst Viral Hepatitis, Dept Infect Dis, Key Lab Mol Biol Infect Dis,Affiliated Hosp 2,Mini, 74 Linjiang Rd, Chongqing 400010, Peoples R China"
通信作者:"Chen, ZW (通讯作者),Chongqing Med Univ, Inst Viral Hepatitis, Dept Infect Dis, Key Lab Mol Biol Infect Dis,Affiliated Hosp 2,Mini, 74 Linjiang Rd, Chongqing 400010, Peoples R China."
来源:LIVER INTERNATIONAL
ESI学科分类:CLINICAL MEDICINE
WOS号:WOS:001154749700001
JCR分区:Q1
影响因子:6.7
年份:2024
卷号:
期号:
开始页:
结束页:
文献类型:Article; Early Access
关键词:MAFLD; MASLD; mortality; NAFLD; NHANES III
摘要:"Background & Aims: Following the classification of metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction-associated steatotic liver disease (MASLD). However, the distinctions in characteristics and mortality outcomes between NAFLD, MAFLD and MASLD remain unclear. Methods: We analysed data from 7519 participants in the third National Health and Nutrition Examination Surveys of United States (US) and their linked mortality until 2019. Survey weight-adjusted multivariable Cox proportional model was used to study the mortality over three terms. Results: The prevalence of NAFLD, MAFLD and MASLD was 18.5%, 19.3% and 20.8%, respectively. Most individuals with NAFLD (94.5%) or MAFLD (100%) can be classified as MASLD, while a relatively low percentage of those with MASLD were also diagnosed with either NAFLD (84.1%) or MAFLD (92.7%). During a median follow-up of 26.9 years, both MAFLD and MASLD were associated with increased risk of all-cause mortality (adjusted hazard ratio [aHR] 1.18, 95% CI 1.04-1.33 and 1.19, 1.06-1.34, respectively), this association was mainly observed in NAFLD-/MASLD+ subgroups. NAFLD was not associated with all-cause mortality. However, all three terms were associated with an increased risk of all-cause mortality in individuals with advanced fibrosis (aHR: 1.71-1.81). Subgroup analyses showed that higher risk of all-cause mortality for both MAFLD and MASLD were observed among older adults (>= 65 year), non-Hispanic whites and those without diabetes. Conclusions: Both MASLD and MALFD were linked to higher all-cause mortality risk, but MASLD identified a greater number of individuals compared to MAFLD."
基金机构:First Batch of Key Disciplines on Public Health in Chongqing
基金资助正文:the First Batch of Key Disciplines on Public Health in Chongqing